Clinical research & EBM · Reference
What is a crossover trial?
A crossover trial is a study design in which each participant receives two or more interventions in sequence, acting as their own control. Comparing treatments within the same person removes between-person variability, making the design efficient for stable, chronic conditions.
Each participant as their own control
In a parallel-group randomized controlled trial, different people receive different interventions. In a crossover trial the same people receive each intervention in turn, so the comparison is made within each participant rather than between separate groups. This within-person comparison strips out the stable individual differences — genetics, baseline severity, lifestyle — that contribute most of the variability between people. As a result a crossover design can detect a given effect with fewer participants than a parallel-group trial, which is why it is attractive when recruitment is difficult.
Periods, sequences and the washout
A crossover trial is organised into treatment periods separated by a washout — an interval with no active treatment, intended to let the effect of one intervention fade before the next begins. The order in which a participant meets the interventions is the sequence, and randomising the sequence balances any effect of period order across the arms. The chief threat to the design is the carryover effect: if an intervention’s effect persists into the next period, it contaminates the comparison. An adequate washout, judged from how long an effect is expected to last, is the main defence.
When the design fits — and when it does not
Crossover designs suit stable, chronic and relapsing conditions where the underlying state returns to a similar baseline between periods, so that each treatment is tested on comparable ground. They are poorly suited to conditions that resolve or progress, or to interventions with lasting or curative effects, because the participant cannot return to their starting state. Dropout part-way through is also more damaging than in a parallel trial, since an incomplete participant contributes to only some comparisons. Reporting follows a CONSORT extension for within-person designs, describing sequences, periods and any carryover assessment.
Key facts
At a glance
- Definition: Each participant receives treatments in sequence
- Control: The participant serves as their own control
- Key interval: Washout period between treatments
- Main threat: Carryover effect from the previous period
- Best for: Stable, chronic, relapsing conditions
- Efficiency: Fewer participants than parallel-group trials
Common questions
FAQ
What is the washout period in a crossover trial?+
The washout period is an interval between treatment periods, with no active treatment, that allows the effect of one intervention to fade before the next begins. An adequate washout is the main safeguard against carryover, where a lingering effect would contaminate the comparison in the following period.
Why use a crossover design instead of a parallel-group trial?+
Because each participant receives every intervention, comparisons are made within the same person, which removes stable between-person differences. This makes the design statistically efficient, so a given effect can be detected with fewer participants — valuable when recruitment is difficult.
When is a crossover trial unsuitable?+
Crossover designs do not suit conditions that resolve, progress or are cured, because the participant cannot return to a comparable baseline between periods. They also struggle when an intervention has lasting effects that carry over, and dropout part-way through is more damaging than in a parallel trial.
Going deeper
Related on CASRAI
- Randomized controlled trial →
- Clinical trial →
- Non-inferiority trial →
- Intention-to-treat →
- Clinical research hub →
Sources
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
